DTC Comparative Ads Will Likely Bloom; FDA Studies How To Evaluate New Species

FDA expects to see an increase in direct-to-consumer drug comparison ads after the Agency for Healthcare Research and Quality completes its comparative effectiveness compendium.

FDA is getting prepared for a jump in direct-to-consumer ads that compare the effectiveness of drugs, which it expects will occur once the Agency for Healthcare Research and Quality completes a compendium of information on the comparative effectiveness of medical treatments.

The agency announced in a Dec. 9 Federal Register notice that it plans to conduct an “Experimental Study...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Marketing & Advertising

More from Compliance